CORV - Correvio Pharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Correvio Pharma Corp.

1441 Creekside Drive
6th Floor
Vancouver, BC V6J 4S7

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees138

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark H. N. CorriganCEO & DirectorN/AN/A1958
Mr. Justin A. Renz CPA, MST, MBACFO & PresN/AN/A1972
Dr. William L. HunterExec. Officer & DirectorN/AN/A1963
Ms. Sheila M. GrantChief Operating OfficerN/AN/AN/A
Mr. David D. McMastersGen. CounselN/AN/A1959
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Corporate Governance

Correvio Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.